Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.
Kiraz CeylanLuciana J JahnsBjoern N LodeKaroline EhlertSilke KietzSascha Troschke-MeurerNikolai SiebertHolger N LodePublished in: Pediatric blood & cancer (2018)
LTI of ch14.18/CHO combined with s.c.IL-2 shows an improved tolerance in subsequent cycles allowing outpatient treatment.